Global Remicade Biosimilar Market Report

As per this study the Global Remicade Biosimilar Market was valued USD 3.59 BN (by revenue) in 2022 and is anticipated to reach USD 44.25 BN by 2030 with a CAGR of 36.9%.

Biosimilar refers to biopharmaceutical drug, which resembles the existing licensed therapeutic drug in terms of quality, efficiency and safety. Remicade is the commercially available brand name of infliximab. Infliximab is the chimeric monoclonal antibody biologic drug used to treat autoimmune diseases such as treat rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis (a type of spinal arthritis), psoriatic arthritis, and the red, scaly skin patches of plaque psoriasis. Biosimilar for remicade are inflectra, renflexis, remsima and flixabi.

Market Dynamics

Rising market competitiveness resulting into a decline in the prices of biosimilar products is driving the market growth. Use of biosimilar products to improve patients' access to medicine by offering financial relief is further fueling the market growth. Also, growing healthcare expenditure followed by a rise in the prevalence of autoimmune medical conditions is again boosting the market demand. However, serious side effects followed by stringent regulatory guidelines for the development of these biosimilar drugs may hinder the market growth.

This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter's five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of remicade biosimilar.

Market Segmentation

The broad remicade biosimilar market has been sub-grouped into disease indication. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.

By Disease Indication

• Ulcerative Colitis
• Rheumatoid Arthritis
• Ankylosing Spondylitis
• Crohn's Disease
• Psoriatic Arthritis
• Plaque Psoriasis

 
Regional Analysis

Furthermore, the report comprises of the geographical segmentation, which mainly focuses on current and forecast demand for remicade biosimilar in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.

Global Remicade Biosimilar Market Share by Region (Representative Graph)



The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the remicade biosimilar market include Johnson & Johnson, Janssen Biotech Inc, Merck & Co., Pfizer Inc, Viatris Inc, Celltrion Inc, Alvogen, Biocon Biologics, Napp Pharmaceuticals, and Nippon Kayaku. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.